NCT01359696View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 11, 2011

Primary Completion Date

May 29, 2014

Study Completion Date

May 29, 2014

Conditions
Solid Tumor
Interventions
DRUG

GDC-0425

Oral escalating dose

DRUG

gemcitabine

Intravenous repeating dose

Trial Locations (3)

37203

Sarah Cannon Cancer Center, Nashville

48201

Karmanos Cancer Institute.., Detroit

94805

Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo, Villejuif

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT01359696 - A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter